BMJ. 1988 Jul 23;297(6643):262-5. doi: 10.1136/bmj.297.6643.262.
The relation of the use of antithyroid drugs to the risk of developing agranulocytosis and aplastic anaemia was evaluated in a population based case-control study with patients from Israel and seven regions in Europe. Data were obtained from cases and hospital controls by interview. Use of antithyroid drugs in the week before the onset of illness was compared in 262 patients with agranulocytosis and 1771 controls. Forty five patients (17%) and five controls (0.3%) had used antithyroid drugs. The relative risk was estimated to be 102 (95% confidence interval 38 to 275) taking into account confounding by other factors, including the use of other drugs. The excess risk for use of antithyroid drugs in any one week was estimated to be 6.3 cases of agranulocytosis per million users. Use of antithyroid drugs in a five month period ending one month before admission to hospital was compared in 135 patients with aplastic anaemia and 2145 controls. Four patients (3%) and five controls (0.2%) had taken drugs; the estimate of relative risk was 9.2 (95% confidence interval 1.8 to 47) after control for confounding. The estimate of excess risk of agranulocytosis with the use of antithyroid drugs was lower than found previously. Although the excess risk for aplastic anaemia was not calculated, these data suggest that it is very low.
在一项以人群为基础的病例对照研究中，对来自以色列和欧洲七个地区的患者使用抗甲状腺药物与发生粒细胞缺乏症和再生障碍性贫血风险之间的关系进行了评估。通过访谈从病例组和医院对照组获取数据。对262例粒细胞缺乏症患者和1771名对照者在发病前一周使用抗甲状腺药物的情况进行了比较。45例患者（17%）和5名对照者（0.3%）使用过抗甲状腺药物。在考虑包括使用其他药物在内的其他因素的混杂作用后，估计相对风险为102（95%置信区间38至275）。估计每百万使用者中抗甲状腺药物使用导致的粒细胞缺乏症额外风险为6.3例。对135例再生障碍性贫血患者和2145名对照者在入院前一个月结束的五个月期间使用抗甲状腺药物的情况进行了比较。4例患者（3%）和5名对照者（0.2%）服用过药物；在控制混杂因素后，相对风险估计值为9.2（95%置信区间1.8至47）。使用抗甲状腺药物导致粒细胞缺乏症的额外风险估计值低于先前发现的值。尽管未计算再生障碍性贫血的额外风险，但这些数据表明其风险非常低。
